EGFR and breast carcinoma: Application of several EGFR/Her2 targeted TKIs to the Her2 amplified breast cancer cell line SK-BR3 led to a highly significant augmentation of PTPIP51/c-Src interaction, whereas the same treatment of BT474 cells, also a Her2 amplified breast cancer cell line, did not alter or even reduce the PTPIP51/c-Src interaction.